{
    "organizations": [],
    "uuid": "23ba213d8954b150be610e6881435647b7c6bd05",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-tetraphase-pharma-enters-exclusive/brief-tetraphase-pharma-enters-exclusive-development-and-commercialization-agreement-with-everest-medicines-idUSFWN1QA0YE",
    "ord_in_thread": 0,
    "title": "BRIEF-Tetraphase Pharma Enters Exclusive Development And Commercialization Agreement With Everest Medicines",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Tetraphase Pharmaceuticals Inc:\n* TETRAPHASE PHARMACEUTICALS ENTERS INTO EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH EVEREST MEDICINES FOR ERAVACYCLINE IN CHINA\n* TETRAPHASE PHARMACEUTICALS - WILL RECEIVE INITIAL UPFRONT PAYMENT OF $7.0 MILLION, MAY RECEIVE CLINICAL AND REGULATORY MILESTONES OF UP TO $16.5 MILLION\n* TETRAPHASE PHARMA-CO ‍MAY RECEIVE CLINICAL, REGULATORY MILESTONES OF UP TO $16.5 MILLION AS WELL AS ANNUAL SALES MILESTONES OF UP TO $20.0 MILLION​\n* TETRAPHASE PHARMACEUTICALS - ‍EVEREST WILL BE SOLELY RESPONSIBLE FOR DEVELOPMENT & COMMERCIALIZATION OF ERAVACYCLINE IN TERRITORIES​\n* TETRAPHASE PHARMACEUTICALS-CO, EVEREST TO ESTABLISH JOINT STEERING COMMITTEE TO REVIEW, OVERSEE ALL OF EVEREST‘S DEVELOPMENT, COMMERCIALIZATION PLANS\n* TETRAPHASE PHARMACEUTICALS - TO BE ELIGIBLE TO RECEIVE DOUBLE DIGIT TIERED ROYALTIES ON NET SALES OF ERAVACYCLINE IN AREAS UNDER AGREEMENT\n* TETRAPHASE PHARMA - ENTERED AGREEMENT WITH EVEREST MEDICINES TO DEVELOP, COMMERCIALIZE ERAVACYCLINE IN HONG KONG, SOUTH KOREA, SINGAPORE, AMONG OTHERS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-21T05:09:00.000+02:00",
    "crawled": "2018-02-21T21:19:28.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "tetraphase",
        "pharmaceutical",
        "inc",
        "tetraphase",
        "pharmaceutical",
        "enters",
        "exclusive",
        "development",
        "commercialization",
        "agreement",
        "everest",
        "medicine",
        "eravacycline",
        "china",
        "tetraphase",
        "pharmaceutical",
        "receive",
        "initial",
        "upfront",
        "payment",
        "million",
        "may",
        "receive",
        "clinical",
        "regulatory",
        "milestone",
        "million",
        "tetraphase",
        "receive",
        "clinical",
        "regulatory",
        "milestone",
        "million",
        "well",
        "annual",
        "sale",
        "milestone",
        "tetraphase",
        "pharmaceutical",
        "solely",
        "responsible",
        "development",
        "commercialization",
        "eravacycline",
        "tetraphase",
        "everest",
        "establish",
        "joint",
        "steering",
        "committee",
        "review",
        "oversee",
        "everest",
        "development",
        "commercialization",
        "plan",
        "tetraphase",
        "pharmaceutical",
        "eligible",
        "receive",
        "double",
        "digit",
        "tiered",
        "royalty",
        "net",
        "sale",
        "eravacycline",
        "area",
        "agreement",
        "tetraphase",
        "pharma",
        "entered",
        "agreement",
        "everest",
        "medicine",
        "develop",
        "commercialize",
        "eravacycline",
        "hong",
        "kong",
        "south",
        "korea",
        "singapore",
        "among",
        "others",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}